279 related articles for article (PubMed ID: 38731863)
1. Characterization of Human B Cell Hematological Malignancies Using Protein-Based Approaches.
Jiménez C; Garrote-de-Barros A; López-Portugués C; Hernández-Sánchez M; Díez P
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731863
[TBL] [Abstract][Full Text] [Related]
2. Bone Marrow Immunohistochemistry and Flow Cytometry in the Diagnosis of Malignant Hematologic Diseases With Emphasis on Lymphomas: A Comparative Retrospective Study.
Landry M; Bienz MN; Sawan B; Temmar R; Beauregard P; Chaunt F; Lavigne J; Knecht H
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):508-512. PubMed ID: 31290784
[TBL] [Abstract][Full Text] [Related]
3. CD43 in the malignant flow cytometry laboratory in 2020.
Sorigue M
Expert Rev Hematol; 2021 Jan; 14(1):123-136. PubMed ID: 33249940
[No Abstract] [Full Text] [Related]
4. Clinical Proteomics of Biofluids in Haematological Malignancies.
Dunphy K; O'Mahoney K; Dowling P; O'Gorman P; Bazou D
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360786
[TBL] [Abstract][Full Text] [Related]
5. [Flow cytometry: application for the diagnosis and the follow-up of hematological malignancies].
Drénou B; Fardel O; Fauchet R; Amiot L
Ann Biol Clin (Paris); 2002; 60(6):663-72. PubMed ID: 12446230
[TBL] [Abstract][Full Text] [Related]
6. Flow Cytometry.
Gascue A; Merino J; Paiva B
Hematol Oncol Clin North Am; 2018 Oct; 32(5):765-775. PubMed ID: 30190016
[TBL] [Abstract][Full Text] [Related]
7. A teaching database for diagnosis of hematologic neoplasms using immunophenotyping by flow cytometry.
Nguyen AN; De J; Nguyen J; Padula A; Qu Z
Arch Pathol Lab Med; 2008 May; 132(5):829-37. PubMed ID: 18466042
[TBL] [Abstract][Full Text] [Related]
8. Integrated Cellular and Plasma Proteomics of Contrasting B-cell Cancers Reveals Common, Unique and Systemic Signatures.
Johnston HE; Carter MJ; Cox KL; Dunscombe M; Manousopoulou A; Townsend PA; Garbis SD; Cragg MS
Mol Cell Proteomics; 2017 Mar; 16(3):386-406. PubMed ID: 28062796
[TBL] [Abstract][Full Text] [Related]
9. Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies.
Daneshmanesh AH; Porwit A; Hojjat-Farsangi M; Jeddi-Tehrani M; Tamm KP; Grandér D; Lehmann S; Norin S; Shokri F; Rabbani H; Mellstedt H; Österborg A
Leuk Lymphoma; 2013 Apr; 54(4):843-50. PubMed ID: 22988987
[TBL] [Abstract][Full Text] [Related]
10. Hematologic Malignancies Discovered on Investigation of Breast Abnormalities.
Alsadi A; Lin D; Alnajar H; Brickman A; Martyn C; Gattuso P
South Med J; 2017 Oct; 110(10):614-620. PubMed ID: 28973700
[TBL] [Abstract][Full Text] [Related]
11. Proteomic analysis of malignant B-cell derived microparticles reveals CD148 as a potentially useful antigenic biomarker for mantle cell lymphoma diagnosis.
Miguet L; Béchade G; Fornecker L; Zink E; Felden C; Gervais C; Herbrecht R; Van Dorsselaer A; Mauvieux L; Sanglier-Cianferani S
J Proteome Res; 2009 Jul; 8(7):3346-54. PubMed ID: 19413345
[TBL] [Abstract][Full Text] [Related]
12. Computational analysis of flow cytometry data in hematological malignancies: future clinical practice?
Duetz C; Bachas C; Westers TM; van de Loosdrecht AA
Curr Opin Oncol; 2020 Mar; 32(2):162-169. PubMed ID: 31876546
[TBL] [Abstract][Full Text] [Related]
13. Characterization of hematologic malignancies by flow cytometry.
Barlogie B; McLaughlin P; Alexanian R
Anal Quant Cytol Histol; 1987 May; 9(2):147-55. PubMed ID: 3300685
[TBL] [Abstract][Full Text] [Related]
14. Notch-ing from T-cell to B-cell lymphoid malignancies.
Mirandola L; Comi P; Cobos E; Kast WM; Chiriva-Internati M; Chiaramonte R
Cancer Lett; 2011 Sep; 308(1):1-13. PubMed ID: 21652011
[TBL] [Abstract][Full Text] [Related]
15. Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future directions.
Orfao A; Schmitz G; Brando B; Ruiz-Arguelles A; Basso G; Braylan R; Rothe G; Lacombe F; Lanza F; Papa S; Lucio P; San Miguel JF
Clin Chem; 1999 Oct; 45(10):1708-17. PubMed ID: 10508115
[TBL] [Abstract][Full Text] [Related]
16. TMTP1, a novel tumor-homing peptide, specifically targets hematological malignancies and their metastases.
Xiao M; Hong Z; Sun L; Wu Y; Zhang N; Liu Y; Luo D; Zhou J; Li C
J Huazhong Univ Sci Technolog Med Sci; 2011 Oct; 31(5):608. PubMed ID: 22038348
[TBL] [Abstract][Full Text] [Related]
17. Modulated multiparametric phosphoflow cytometry in hematological malignancies: technology and clinical applications.
Covey TM; Cesano A
Best Pract Res Clin Haematol; 2010 Sep; 23(3):319-31. PubMed ID: 21112033
[TBL] [Abstract][Full Text] [Related]
18. Flow Cytometry and Effusions in Lymphoproliferative Processes and Other Hematologic Neoplasias.
Bode-Lesniewska B
Acta Cytol; 2016; 60(4):354-364. PubMed ID: 27578145
[TBL] [Abstract][Full Text] [Related]
19. Utility and proposed algorithm of CSF flow cytometry in hematologic malignancies.
Tawfik B; Brown L; Fuda F; Chen W; Niu S; Sailors J; Sadeghi N
Ann Hematol; 2018 Sep; 97(9):1707-1716. PubMed ID: 29680874
[TBL] [Abstract][Full Text] [Related]
20. Exosomal microRNA panels as biomarkers for hematological malignancies.
Moloudizargari M; Hekmatirad S; Mofarahe ZS; Asghari MH
Curr Probl Cancer; 2021 Oct; 45(5):100726. PubMed ID: 33752898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
